North American Association of Central Cancer Registries

American Cancer Society Releases New Colorectal Cancer Statistics; Rapid Shifts to More Advanced Disease and Younger People

Retrieved on: 
Wednesday, March 1, 2023

ATLANTA, March 1, 2023 /PRNewswire/ -- Colorectal cancer is swiftly shifting to more advanced disease and younger individuals according to Colorectal Cancer Statistics 2023, a new report on cancer facts and trends by the American Cancer Society (ACS).

Key Points: 
  • ATLANTA, March 1, 2023 /PRNewswire/ -- Colorectal cancer is swiftly shifting to more advanced disease and younger individuals according to Colorectal Cancer Statistics 2023, a new report on cancer facts and trends by the American Cancer Society (ACS).
  • Overall, in 2023, an estimated 153,020 people will be diagnosed with CRC in the U.S., and 52,550 people will die from the disease.
  • These major findings are to be published today in CA: A Cancer Journal for Clinicians , alongside its consumer-friendly companion, Colorectal Cancer Facts & Figures 2023-2025, available on cancer.org .
  • "These highly concerning data illustrate the urgent need to invest in targeted cancer research studies dedicated to understanding and preventing early-onset colorectal cancer," said Dr. Karen E. Knudsen , CEO of the American Cancer Society.

Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients

Retrieved on: 
Monday, October 25, 2021

SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ --Accuray Incorporated(NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.

Key Points: 
  • SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ --Accuray Incorporated(NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.
  • The addition of radiotherapy can extend survival that may be offset by the development of a secondary cancer like lung tumors many years following treatment.
  • This study reinforces the unparalleled accuracy of a 4-like robotic CyberKnife platform and shows its tremendous potential as a treatment for early-stage breast cancer," said Suzanne Winter, president at Accuray.
  • Breast cancer stage distribution and number of new cases were obtained from the North American Association of Central Cancer Registries (NAACCR).